Quote:
Originally Posted by Penn
TJ, No doubt.
Here is something interesting. While at g school, I had a professor that worked for BMS, he stated the rational behind what comes to market is revenue driven. e.g., if x dollars are to fund research, the goal will be to fund the most profitable, not the necessarily the most needed for a cure. When Covid vax came out we understood the fully realized statement he made.
That said, his model for investment vs ROI, we employ when constructing our menus. We have been very please ever since.
|
Penn, sorry for this late reply, but I have been off-line. You have poimted out the issue and the dichotomy of investment strategies. In the cases of 'single focus' investments such as you personal portfolio or the next 'me too' pharma product your BMS professor is correct. However, once in a while, a truly transformational new drug candidate emerges. In these cases the rules should not apply. If current Pharma thinking existed in Alexander Fleming's day, Penicillin would not have been developed!
Or if it had, penicillin's retail cost would have made it unaffordable to most.